Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
Keywords:
Materias Investigacion::Ciencias de la Salud::Hepatología
Hepatocellular carcinoma
Artificial intelligence-based pathology
Atezolizumab–bevacizumab
Project:
ANR-10-INBS-09-08
Citation:
Zeng, Q. (Qinghe); Klein, C. (Christophe); Caruso, S. (Stefano); et al. "Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study". The Lancet Oncology. 24, 2023, 1411 - 1422
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.